论文部分内容阅读
目的观察静脉补铁与口服铁剂治疗肾性贫血的临床效果。方法将30例尿毒症规律透析半年以上,已常规应用促红素3个月以上,但贫血纠正不满意的患者随机分成静脉铁组和口服铁组,每组15人,静脉铁组每周静脉补充右旋糖酐铁2次,每次100mg;口服铁组口服硫酸亚铁1片,每日1次,用药10周。用药前后测定病人Hb、Hct、血清四铁、铁蛋白、肝肾功,并监测有无药物相关不良反应。结果两组用药10周后Hb、Hct、血清四铁、铁蛋白均有升高,但两者间有明显差异(P<0.05)。口服铁组不良反应少于静脉铁组,但没有显著差异(P>0.05)。结论静脉补铁能更有效纠正尿毒症肾性贫血。
Objective To observe the clinical effect of intravenous iron supplementation and oral iron on renal anemia. Methods 30 cases of uremia regular dialysis for more than six months, the conventional application of erythropoietin more than 3 months, but patients not satisfied with anemia correction were randomly divided into intravenous iron group and oral iron group, each group of 15 people, intravenous iron group weekly vein Iron supplementation of dextran 2 times, each 100mg; oral iron group oral administration of ferrous sulfate 1, 1 day, medication for 10 weeks. Before and after treatment of patients measured Hb, Hct, serum four iron, ferritin, liver and kidney function, and to monitor for drug-related adverse reactions. Results Hb, Hct, serum ferritin and ferritin were increased in both groups after 10 weeks of treatment, but there was a significant difference between the two groups (P <0.05). Oral iron adverse reaction less than intravenous iron group, but no significant difference (P> 0.05). Conclusion Intravenous iron supplementation can more effectively correct uremic renal anemia.